Research has been published in “Immunology of Science Newspapers”
Connecticut: In a new study led by Akiko Iwasaki of Yale, professor of immunobiology at Waldemar Von Zedtwitz, intranasal vaccination has been shown to offer large-scale protection against heterologous respiratory viruses in mice. The research has been published in the “Science Immunology Journal”.
The best immune defense occurs at the gate, protecting against viruses that attempt to enter, “said Iwasaki, lead author of the study. Mucous membranes contain their own immune defense system that fights pathogens from the air. or food. When challenged, these barrier tissues produce B lymphocytes which in turn secrete antibodies against immunoglobin A (IgA) antibodies.
Unlike vaccines which elicit a wide immune response system, IgA antibodies act locally on the mucous surfaces of the nose, stomach and lungs. While the protective role of IgA- In collaboration with researchers at the Mount Sinai Icahn School of Medicine in New York, the laboratory Iwasaki wondered if activation of the IgA response could also produce a localized immune response against the ventilator and the virus.
Tested a protein-based vaccine designed to initiate a response i unitary IgA, given to mice via injections, as is commonly done with systemic immunizations, and also intranasally. They then exposed the mice to several strains of the influenza virus. They found that mice given the intranasal vaccine were much better protected against respiratory flu than those given the injections.
The nasal vaccines, but not the injection, also induced antibodies that protected the animals against various strains of influenza, not just the strain the vaccine was supposed to protect them from. The Yale team is currently testing nasal vaccine strains against strains of COVID in animal models. “While vaccine injections and nasal vaccines increased antibody levels in the blood of mice, only the nasal vaccine allowed the secretion of IgA in the lungs of mice, where respiratory viruses must settle for infect the host, “Iwasaki said.
To be safe and effective in humans, Iwasaki expects to be used in conjunction with current vaccines and boosters that work system-wide in order to add system boosters immune source of infection The other co-original authors of the study are Ji Eun Oh, Eric Song and Miyu Moriyama, all of Yale.
